Adoption of Updated EDGAR Filer Manual

Federal Register / Vol. 91, No. 73 / Thursday, April 16, 2026 / Rules and Regulations 20335 1See Rule 301 of Regulation S–T. 2EDGAR Filer Access and Account Management, Release No. 33–11313 (Sept. 27, 2024) [89 FR 106168 (December 27, 2024)]. by removing §§ 28.405 and 28.410, because they merely restate 31 U.S.C. 1352(c)(3) and 31 U.S.C. 1352(f), and by removing 28.600 and 28.605, because they establish reporting requirements that are no longer statutorily required or warranted (91 FR 1724). As stated in the proposed rule, these removals are intended to streamline part 28, eliminate regulatory clutter, reduce the possibility of confusion, and promote administrative efficiency. Public Comment Commerce requested comment on the proposed rule. The comment period closed on February 17, 2026. No comments were received during the public comment period, and no changes were made from the proposed rule. Classification Executive Order 12866 This rule has been determined to be not significant for the purposes of Executive Order 12866. Executive Order 14192 This rule is an Executive Order 14192 deregulatory action. Regulatory Flexibility Act (RFA) The Chief Counsel for Regulation of the Department of Commerce certified to the Chief Counsel for Advocacy of the Small Business Administration (SBA) that this rule will not have a significant economic impact on a substantial number of small entities. The factual basis for the certification was published in the proposed rule and is not repeated here. No comments were received regarding this certification. As a result, a regulatory flexibility analysis was not required, and none was prepared. Paperwork Reduction Act This rule contains no new information collection requirements under the Paperwork Reduction Act of 1995. List of Subjects in 15 CFR Part 28 Administrative practice and procedure, Government contracts, Grant programs, Grants administration, Loan programs, Lobbying, Penalties, Reporting and recordkeeping requirements. Dated: April 13, 2026. Paul Dabbar, Deputy Secretary of Commerce. Accordingly, for the reasons set forth above, part 28 of title 15 of the Code of Federal Regulations is amended as follows: PART 28—NEW RESTRICTIONS ON LOBBYING ■ 1. The authority citation for part 28 continues to read as follows: Authority: Sec. 319, Pub. L. 101–121 (31 U.S.C. 1352; 5 U.S.C. 301; Sec. 4, as amended, and sec. 5, Pub. L. 101–410, 104 Stat. 890 (28 U.S.C. 2461 note); Pub. L. 104– 134, 110 Stat. 1321, 28 U.S.C. 2461 note. Subpart D—Penalties and Enforcement § 28.405 [Removed and Reserved] ■ 2. Remove and reserve § 28.405. § 28.410 [Removed and Reserved] ■ 3. Remove and reserve § 28.410. Subpart F [Removed and Reserved] ■ 4. Remove and reserve subpart F. [FR Doc. 2026–07431 Filed 4–15–26; 8:45 am] BILLING CODE 3510–DT–P SECURITIES AND EXCHANGE COMMISSION 17 CFR Part 232 [Release Nos. 33–11411; 34–105011; 39– 2562; IC–36018] Adoption of Updated EDGAR Filer Manual AGENCY: Securities and Exchange Commission. ACTION: Final rule. SUMMARY: The Securities and Exchange Commission (‘‘Commission’’) is adopting amendments to Volumes I and II of the Electronic Data Gathering, Analysis, and Retrieval system Filer Manual (‘‘EDGAR Filer Manual’’ or ‘‘Filer Manual’’) and related rules and forms. EDGAR Release 26.1 was deployed in the EDGAR system on March 16, 2026. DATES: Effective date: April 16, 2026. The incorporation by reference of the revised Filer Manual volumes is approved by the Director of the Federal Register as of April 16, 2026. FOR FURTHER INFORMATION CONTACT: For questions regarding the amendments to Volume I or II of the Filer Manual, please contact Rosemary Filou, Deputy Director and Chief Counsel, Laurita Finch, Senior Special Counsel, or Dan Chang, Senior Special Counsel, in the EDGAR Business Office at (202) 551– 3900. For questions regarding changes to the Fee Exhibit Preparation Tool (FEPT), ACH limits, or filing fee exhibit warnings being changed to suspensions, please contact Luba Dinits, Senior Accountant, Office of Financial Management, at (202) 551–3839 or Mark W. Green, Senior Special Counsel, Division of Corporation Finance, at (202) 551–3430. For questions regarding Forms 3, 4, or 5 with regards to filing obligations for directors or officers of foreign private issuers or changes to Schedule 13D and 13G filings to support multiple CUSIPs, please contact the Disclosure Management Office in the Division of Corporation Finance at (202) 551–2076. For questions regarding the change to Form X–17A–5 Part III in terms of the oath or affirmation no longer being required to be notarized, please contact Raymond Lombardo, Assistant Director, at (202) 551–5755 or Valentina Deng, Special Counsel, at (202) 551–5778 in the Division of Trading and Markets. For questions regarding the change to Item 6 of Form 13H, please contact Kathleen Gross at (202) 551–5305 in the Division of Trading and Markets. SUPPLEMENTARY INFORMATION: We are adopting an updated Filer Manual, Volume I: ‘‘General Information,’’ Version 43 (effective March 16, 2026) and Volume II: ‘‘EDGAR Filing,’’ Version 77 (March 16, 2026) and amendments to 17 CFR 232.301, Rule 301 of Regulation S–T. The updated Filer Manual Volumes are incorporated by reference into the Code of Federal Regulations. I. Background The Filer Manual contains information needed for filers to make submissions on EDGAR. Filers must comply with the applicable provisions of the Filer Manual in order to assure the timely acceptance and processing of filings made in electronic format.1 Filers must consult the Filer Manual in conjunction with our rules governing mandated electronic filings when preparing documents for electronic submission. II. Amendments to Volume I of the Filer Manual Volume I of the Filer Manual, which sets forth the requirements for becoming an EDGAR filer, was amended to reflect the implementation of technical changes adopted in EDGAR Filer Access and Account Management, Release No. 33– 11313 (Sept. 27, 2024) (‘‘EDGAR Next rulemaking’’).2 Among other things, the EDGAR Next rulemaking eliminated the use of EDGAR access codes such as passwords and passphrases and instead required the use of individual account VerDate Sep<11>2014 17:05 Apr 15, 2026 Jkt 268001 PO 00000 Frm 00019 Fmt 4700 Sfmt 4700 E:\FR\FM\16APR1.SGM 16APR1 lotter on DSK8BHNXB4PROD with RULES1

20336 Federal Register / Vol. 91, No. 73 / Thursday, April 16, 2026 / Rules and Regulations 3 5 U.S.C. 553(b)(A). 4 5 U.S.C. 601 through 612. 5 5 U.S.C. 804(3)(c). 6 5 U.S.C. 553(d)(3). 7 15 U.S.C. 77f, 77g, 77h, 77j, and 77s(a). 8 15 U.S.C. 78c, 78l, 78m, 78n, 78o, 78o–4, 78w, and 78ll. 9 15 U.S.C. 77sss. 10 15 U.S.C. 80a–8, 80a–29, 80a–30, and 80a–37. credentials and individual permissions as maintained in the EDGAR Filer Management dashboard. Pursuant to the EDGAR Next rulemaking, these EDGAR access codes were discontinued on December 19, 2025, however, corresponding changes to the EDGAR Filer Manual planned for December 2025 were not implemented due to the impact of the lapse in appropriations from October 1, 2025, through November 12, 2025. Consequently, Section 4 of Volume I related to the use of EDGAR access codes has been removed from the EDGAR Filer Manual and Sections 5 through 9 of Volume I are renumbered as Sections 4 through 8. Volume I was also amended to clarify the situations in which a cover letter or other supporting information must be included in a Form ID application for access for an existing CIK. Section 3(c) the Filer Manual was amended to clarify that a cover letter is required for all applicants that seek access to an existing EDGAR account, but other supporting information such as official documents from the relevant Secretary or State or Register of Corporations that identify the signatory listed on the Form ID application as an ‘‘authorized individual’’ is only required if applicants assert that they assumed legal control of the filer listed on the existing account but did not receive EDGAR access information from the filer. III. Amendments to Volume II of the Filer Manual EDGAR was updated pursuant to EDGAR Release 26.1, and corresponding amendments to Volume II of the Filer Manual were made to reflect those changes, as described below. Filing Fee Related Changes Starting March 16, 2026, EDGAR generally will suspend filings rather than issue warnings for incorrect or incomplete structured filing fee-related information for all filers. EDGAR will continue to issue warnings in some instances. Separately, the ACH limit for filing fees changed from a maximum of $99,999,999.99 per transaction to $24,999,999.99 per transaction. Filers that need to exceed that limit may make multiple transactions. Schedule 13D and 13G As of March 16, 2026, Schedules 13D and 13G (including associated submission types) have been updated to accommodate up to 20 CUSIP numbers. At least one CUSIP entry is required. Inline XBRL Guidance Information regarding the submission of Inline XRL documents was removed from Chapter 5.2.5. That same information has been incorporated into the EDGAR XBRL Guide, which is referenced in Chapter 5.2.5 and which contains additional information and guidance regarding the submission of Inline XBRL documents for EDGAR. Notarization of Oath or Affirmation in Form X–17A–5 Part III As of March 24, 2025, Form X–17A– 5 Part III no longer requires the oath or affirmation to be notarized. Therefore, the text and checkbox acknowledging notarization of the oath or affirmation have been removed from the submission template for Form X–17A–5 Part III on the EDGAR Filing website and are no longer required in filer-constructed submissions. Update to Item 6 of Form 13H On October 3, 2025, the submission template for Form 13H (and associated submission types) on the EDGAR Filing website was updated to allow reordering of entries in Item 6 (List of broker￾dealers at which the large trader or its securities affiliates has an account), including additions and deletions in the middle of the list per filer preference. This change does not impact the XML technical specifications for Form 13H. Forms 3, 4, and 5 Beginning March 18, 2026, each director or officer of a foreign private issuer that has securities registered under Section 12(b) or 12(g) of the Securities Exchange Act of 1934 (‘‘Exchange Act’’) must file reports under Section 16(a) of the Exchange Act, pursuant to the Holding Foreign Insiders Accountable Act (enacted December 18, 2025). Starting March 18, 2026, Forms 3, 4, and 5 include a Country field that requires a country name for all reporting persons and a field to provide a Foreign Trading Symbol. III. Amendments to Rule 301 of Regulation S–T Along with the adoption of the updated Filer Manual, we are amending Rule 301 of Regulation S–T to provide for the incorporation by reference of the revised Filer Manual into the Code of Federal Regulations. This incorporation by reference is approved by the Director of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. The updated EDGAR Filer Manual is available at https://www.sec.gov/edgar/ filer-information/current-edgar-filer￾manual. IV. Administrative Law Matters Because the Filer Manual and rule amendments relate solely to agency procedures or practice and do not substantially alter the rights and obligations of non-agency parties, publication for notice and comment is not required under the Administrative Procedure Act (‘‘APA’’).3 It follows that the amendments do not require analysis under requirements of the Regulatory Flexibility Act 4 or a report to Congress under the Small Business Regulatory Enforcement Fairness Act of 1996.5 The Office of Management and Budget has determined that this action is not a significant regulatory action as defined in Executive Order 12866, as amended, and therefore it was not subject to Executive Order 12866 review. The updated Filer Manual became operational on March 16, 2026, when EDGAR Release 26.1 was deployed in the EDGAR system. The effective date for use of the updated Filer Manual and the related rule amendments is April 16, 2026. In accordance with the APA,6 we find that there is good cause to establish an effective date less than 30 days after publication of these rules. The Commission believes that establishing an effective date less than 30 days after publication of these rules is necessary to coordinate the effectiveness of the updated Filer Manual with the related system upgrades. V. Statutory Basis We are adopting the amendments to Regulation S–T under the authority in sections 6, 7, 8, 10, and 19(a) of the Securities Act of 1933,7 sections 3, 12, 13, 14, 15, 15B, 23, and 35A of the Securities Exchange Act of 1934,8 section 319 of the Trust Indenture Act of 1939,9 and sections 8, 30, 31, and 38 of the Investment Company Act of 1940.10 List of Subjects in 17 CFR Part 232 Incorporation by reference, Reporting and recordkeeping requirements, Securities. Text of the Amendments In accordance with the foregoing, title 17, chapter II of the Code of Federal Regulations is amended as follows: VerDate Sep<11>2014 17:05 Apr 15, 2026 Jkt 268001 PO 00000 Frm 00020 Fmt 4700 Sfmt 4700 E:\FR\FM\16APR1.SGM 16APR1 lotter on DSK8BHNXB4PROD with RULES1

Federal Register / Vol. 91, No. 73 / Thursday, April 16, 2026 / Rules and Regulations 20337 PART 232—REGULATION S–T— GENERAL RULES AND REGULATIONS FOR ELECTRONIC FILINGS ■ 1. The general authority citation for part 232 continues to read as follows: Authority: 15 U.S.C. 77c, 77f, 77g, 77h, 77j, 77s(a), 77z–3, 77sss(a), 78c(b), 78l, 78m, 78n, 78n–1, 78o(d), 78w(a), 78ll, 80a–6(c), 80a–8, 80a–29, 80a–30, 80a–37, 7201 et seq.; and 18 U.S.C. 1350, unless otherwise noted.

■ 2. Section 232.301 is revised to read as follows: § 232.301 EDGAR Filer Manual. Filers must prepare electronic filings in the manner prescribed by the EDGAR Filer Manual, promulgated by the Commission, which sets forth the technical formatting requirements for electronic submissions. The requirements for becoming an EDGAR Filer and updating company data are set forth in the EDGAR Filer Manual, Volume I: ‘‘General Information,’’ Version 43 (effective March 16, 2026). The requirements for filing on EDGAR are set forth in the updated EDGAR Filer Manual, Volume II: ‘‘EDGAR Filing,’’ Version 77 (March 16, 2026). All EDGAR material referenced in this paragraph is incorporated by reference into this section with the approval of the Director of the Federal Register under 5 U.S.C. 552(a) and 1 CFR part 51. You must comply with these requirements in order for documents to be timely received and accepted. The EDGAR Filer Manual is available for inspection at the Commission and at the National Archives and Records Administration (NARA). The EDGAR Filer Manual is available for website viewing and printing in the Commission’s Public Reference Room, 100 F Street NE, Washington, DC 20549; (202) 551–3900; Library@sec.gov, on official business days between the hours of 10 a.m. and 3 p.m. Operating conditions may limit access to the Commission’s Public Reference Room. The EDGAR Filer Manual may also be obtained from https://www.sec.gov/ edgar/filerinformation/current-edgar￾filer-manual. For information on the availability of the EDGAR Filer Manual at NARA, visit www.archives.gov/ federal-register/cfr/ibr-locations or email fr.inspection@nara.gov. By the Commission. Dated: March 16, 2026. Vanessa A. Countryman, Secretary. [FR Doc. 2026–07474 Filed 4–15–26; 8:45 am] BILLING CODE 8011–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 510, 516, 520, 522, 524, and 558 [Docket No. FDA–2025–N–0002] New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor; Change of Sponsor Address AGENCY: Food and Drug Administration, HHS. ACTION: Final rule; technical amendments. SUMMARY: The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs), abbreviated new animal drug applications (ANADAs), and conditionally approved new animal drug applications (CNADAs) during October, November, and December 2025. The animal drug regulations are also being amended to improve their accuracy and readability. DATES: This rule is effective April 16, 2026. FOR FURTHER INFORMATION CONTACT: James Delaney, Center for Veterinary Medicine, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740. james.delaney@fda.hhs.gov, 240–402– 5677. SUPPLEMENTARY INFORMATION: I. Approval of Applications FDA is amending the animal drug regulations to reflect approval actions for NADAs, ANADAs, and CNADAs during October, November, and December 2025, as listed in table 1. Documentation of environmental review required under the National Environmental Policy Act, summaries of the basis of approval under the Freedom of Information Act (FOIA summaries), and marketing exclusivity and patent information are available at Animal Drugs @FDA: https://animaldrugsatfda. fda.gov/adafda/views/#/search. TABLE 1—ORIGINAL, CONDITIONAL, AND SUPPLEMENTAL APPLICATIONS APPROVED DURING OCTOBER, NOVEMBER, AND DECEMBER 2025 Date of approval Application No. Sponsor (drug labeler code 1) Product name Effect of the action 21 CFR sections October 20, 2025 ....... 141–581 Elanco US Inc. (058198) ................ CREDELIO QUATTRO (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets). Supplemental Approval ................... 520.1287 October 21, 2025 ....... 200–825 Felix Pharmaceuticals Pvt. Ltd. (086101). Clomipramine Hydrochloride Tab￾lets. Original approval as a generic copy of NADA 141–120. 520.455 October 21, 2025 ....... 141–574 Pharmgate Inc. (069254) ................ PENNITRACIN MD 50G (bacitracin methylenedisalicylate Type A medicated article) and MONTEBAN (narasin Type A medicated article). Original approval ............................. 558.363 October 24, 2025 ....... 141–494 Elanco US Inc. (058198) ................ CREDELIO (lotilaner) ...................... Supplemental approval ................... 520.1286 December 5, 2025 ...... 200–710 Dechra Veterinary Products LLC (017033). Maropitant Citrate (maropitant cit￾rate) injectable solution. Original approval as a generic copy of NADA 141–263. 522.1315 December 17, 2025 .... 141–619 Elanco US Inc. (058198) ................ CREDELIO QUATTRO CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets). Conditional approval ....................... 516.1287 December 18, 2025 .... 141–614 Anivive Lifesciences, Inc. (086121) LAVERDIA (verdinexor tablets) ...... Original approval from conditional approval. 520.2700 516.2980 December 19, 2025 .... 141–576 Dechra, Ltd. (043264) ..................... COSACTHEN (cosyntropin injec￾tion). Original approval ............................. 522.500 December 19, 2025 .... 141–273 Boehringer Ingelheim Animal Health USA, Inc. (000010). VETMEDIN (pimobendan) .............. Supplemental approval ................... 520.1780 VerDate Sep<11>2014 17:05 Apr 15, 2026 Jkt 268001 PO 00000 Frm 00021 Fmt 4700 Sfmt 4700 E:\FR\FM\16APR1.SGM 16APR1 lotter on DSK8BHNXB4PROD with RULES1